A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Suramin sodium (Primary) ; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 06 Jul 2007 New trial record.